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Abstract
Background: Sirolimus is recently reported to have antitumour effects on a large variety of
cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24
bladder cancer cells.
Methods: T24 bladder cancer cells were treated with various concentrations of sirolimus. MTT
assay was used to evaluate the proliferation inhibitory effect on T24 cell line. The viability of T24
cell line was determined by Trypan blue exclusion analysis.
Results: Sirolimus inhibits the growth of bladder carcinoma cells and decreases their viability.
Significant correlations were found between cell proliferation and sirolimus concentration (r =
0.830; p < 0.01) as well as between cell viability and sirolimus concentration (r = -0.896; p < 0.01).
Conclusion: Sirolimus has an anti-proliferation effect on the T24 bladder carcinoma cell line. The
information from our results is useful for a better understanding sirolimus's anti-proliferative
activity in the T24 bladder cancer cell line.
Background
Bladder cancer is the second most common urologic
malignancy and accounts for approximately 90% of can-
cers of the urinary tract. Is the fourth most incident cancer
in male and ninth in females [1]. In industrialized coun-
tries, more than 90% of cases are originate in the urothe-
lial epithelial cells (called urothelial cell carcinoma) [2].
At diagnosis, 75% are non-invasive bladder cancer. The
invasive bladder cancers may spread outside the bladder
and affect other organs. Bladder cancer's staging, treat-
ment and prognosis depend on how deeply it has invaded
urinary bladder [3].
Fortunately, about 80% of patients with non-muscle inva-
sive disease can be successfully treated using the surgery.
Historically, two-thirds of patients have tumour recur-
rence within 5 years. High-grade tumours have a signifi-
cantly worse prognosis. Both high-grade T1 tumours and
carcinoma in situ have the potential to progress and even
metastasize [4]. Patients with invasive bladder cancer
require a radical cystectomy. Controversy exists as to
whether neoadjuvant or adjuvant chemotherapy
improves survival in patients with invasive bladder can-
cer, despite a number of randomised controlled trials. So
far there are no data to confirm what is the best combina-
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tion of treatments (neoadjuvant chemotherapy, adjuvant
with or without radiotherapy) to treat invasive bladder
cancer [5]. The modest results with currently drugs, sug-
gest the urgent need to identify new agents [6]. Sirolimus
is a macrocyclic lactone that was first discovered as a prod-
uct of the soil bacteria Streptomyces hygroscopicus. It was
originally used as an immunosuppressant drug to help
prevent rejection in organ transplantation, particularly in
kidney transplant operations, but the authors of a number
of recent reports have indicated that it may have other
potential biological effects as an anti-cancer medicine
[7,8]. Both the immunosuppressive and anti-cancer prop-
erties of sirolimus are due to the inhibition of the mam-
malian target of the sirolimus (mTOR) signalling
pathway, which controls mRNA translation and induces
angiogenesis and cell proliferation. Angiogenesis and a
high proliferative index correspond to a poor prognosis
for urothelial bladder cancer patients [9,10]. Sirolimus
forms a complex with the immunophilin prolyl isomerase
FK binding protein complex (FKBP-12) that binds with
high affinity to mTOR [11,12]. This interaction inhibits
mTOR kinase activity and subsequently decreases the
phosphorylation of 4E binding protein-1 and the inhibi-
tion of the 40S ribosomal protein p70 S6 kinase [13-15].
Sirolimus's antineoplasic effects have been related to its
capacity to inhibit the translation machinery involved in
the regulation of G1- to S-phase transition in cell cycle
[16,17]. Cell growth and proliferation in numerous can-
cer types are often regulated by the mammalian target of
sirolimus (mTOR) pathway through p7056 kinase, ribos-
omal S6 protein, and eukaryotic initiation factor 4 E-bind-
ing protein 1 [18]. Recently there has been an enormous
increase in our understanding of the molecular mecha-
nisms underlying sirolimus's therapeutic anti-cancer
properties. Alterations in the pathway regulating mTOR
occur in many solid malignancies including bladder can-
cer. In vitro and in vivo models of bladder cancer have
established the importance of the mTOR pathway in con-
trolling cancer progression and metastasis [19]. The T24
cell line has been established from a highly malignant
grade III human urinary bladder carcinoma [20]. This cell
line can be easily grown in vitro and has been extensively
used to evaluate the therapeutic effects of several antican-
cer drugs. Here, we describe the preliminary results of the
study of the therapeutic effect of sirolimus against human
T24 bladder cancer cell line in vitro using 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay for assessing cell proliferation and Trypan blue for
assessing cell viability.
Linear relationship between the proliferation inhibitory rate (%) and sirolimus concentration (y = 0.2074x + 23.299; r2 =  0.6882) Figure 1
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Materials and methods
Cell culture
Cell line T24 was provided by a German collection of
microorganisms and cell cultures (DSMZ, Düsseldorf,
Germany). Cells were grown as a monolayer in complete
RPMI (RPMI-1640 medium supplemented with 10% fetal
calf serum, 100 U/mL penicillin and l00 μg/mL strepto-
mycin), in a humidified atmosphere with 7% CO2-93%
air at 37°C. Under these conditions, the plating efficiency
was 70–90% and the doubling time was 9–10 h. Single
cell suspensions were obtained by trypsinization of mon-
olayer cultures.
Drugs
Sirolimus was purchased from Wyeth (Rapamune).
Cell proliferation
The anti-proliferative capacity of the treatments was
assessed by the MTT [21]. This is based on the reduction
of MTT by mitochondrial dehydrogenase of intact cells to
a purple formazan product. Using a Neubauer counting
chamber cells were counted and 2 × 104 cells were seeded
in 1 ml of medium in a 96-well culture plates and allowed
to attach for 24 hours. Cells were treated with sirolimus (5
ng/mL, 10 ng/mL, 40 ng/mL, 60 ng/mL, 100 ng/mL, 150
ng/mL, 200 ng/mL, and 250 ng/mL) for 72 h, these doses
were based on results published by other researchers
[22,23]. Each of the concentrations above was regarded as
one treated group while there was no sirolimus in the con-
trol group. After incubation, cell proliferation was evalu-
ated by MTT assay according to the manufacturer's
instructions. The MTT solution (20 μL, 5 mg/ml) was
added to each well 3 h prior to the end of the 72 h chem-
ical treatment exposure period. The media were removed
at the end of the 72 h exposure period. The insoluble pur-
ple formazan crystals were dissolved in 100 μL DMSO/
well and the absorbance was detected at 570 nm and 690
nm using a spectrophotometer (U 2000, Hitachi). The
proliferation inhibitory rate percentage was calculated as
follows: proliferation inhibitory rate (%)= 1-(A570-A690)
of experimental wells/(A570-A690) of control wellsX100.
Assays were performed in triplicate.
Assay of cell viability
The viability of T24 cell line was determined by Trypan
blue exclusion analysis. 0.2 ml of the cells suspension
treated with sirolimus at various concentrations were
transferred to test tubes with 0.5 ml of 0.4% Trypan blue
Linear relationship between the cell viability rate (%) and sirolimus concentration (y = -0.1993x + 85.162; r2 = 0.8023) Figure 2
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solution and 0.3 ml of HBSS and mixed thoroughly.
Allow to stand for 5 to 15 minutes. The percentage of via-
ble cells was evaluated under the field microscope. Assays
were performed in triplicate.
Statistical analysis
All experiments were performed in triplicate and data
were expressed as mean values ± SD. The Pearson product-
moment correlation coefficient was used to evaluate the
correlation (linear dependence) of cell proliferation, via-
bility and sirolimus concentration. Data were analysed
using SPSS 12 statistical software (SPSS Inc. USA) and sta-
tistical significance was set at p < 0.05.
Results
Cell proliferation
The results of the MTT assay to detect sirolimus-induced
anti-proliferative activity in T24 cell line are found in
Table 1. T24 cancer cells were treated with various concen-
trations of sirolimus. As shown in Figure 1, sirolimus had
growth inhibition effects on T24 cancer cells in a dose-
dependent manner. Statistically, anti-proliferative activity
was correlated with sirolimus concentration, the Pearson
correlation of these two markers is r = 0.830 to p < 0.01.
Cell viability
The results of cell viability after the incubation of the T24
cell line with sirolimus at different concentrations are dis-
played in Figure 2. It can be seen from the figure that there
was a concentration-dependent decrease in cell viability
for all concentrations tested. A significant correlation was
found between cell viability and sirolimus concentration
(r = -0.896, p < 0.01).
Discussion
The findings of the present study revealed that sirolimus
inhibits T24 bladder cancer cell proliferation and decrease
the cell viability including in clinical dose of this mTOR
inhibitor. These data may be relevant if we remember the
action of the mTOR pathway. mTOR is a 290 kDa serine-
threonine kinase that regulates both cell growth and cell
cycle progression through its ability to integrate signals
from nutrient and growth factor stimuli [24]. Tumour
angiogenesis may depend on mTOR signalling. Hypoxia
induces production of vascular endothelial cell growth
factor (VEGF) by tumour and stromal cells which may be
partly controlled by mTOR signaling and through PI3K-
Akt-mTOR pathway [25]. Thus, the anti-tumour effects
noted by inhibiting mTOR may be related to antiprolifer-
ative effects within tumour cells as well endothelial cells.
Upstream effectors that signal through mTOR may up-reg-
ulate mTOR gene. Wu X et al (2004) showed that a spe-
cific inhibitor of PI3 kinase enzyme activity, Ly294002,
potently suppressed the invasive properties of three highly
invasive bladder tumour cell lines and 55% of primary
tumours from patients with bladder cancer had markedly
high levels of phosphorylated Akt [26]. Thus, the inhibi-
tion of mTOR may inhibit abnormal cell proliferation,
tumour angiogenesis, and abnormal cell metabolism and
potentially enhance the efficacy of other cancer treat-
ments. The biological mechanisms responsible for anti-
proliferative effect of sirolimus and the role of PI3K-Akt-
mTOR pathway are under investigation [27]. Tanaka and
Grossman (2003) demonstrate that PTEN can induce
growth suppression and increase sensitivity to doxoru-
bicin in bladder cancer cells and suggest that the PTEN
gene and its pathways can be therapeutic targets for blad-
der cancer. To emphasize that, no results have been yet
published on the activity of mTOR inhibitors against T24,
or other, bladder cancer cell lines. Luan FL et al. (2002)
showed that, sirolimus treatment alone, or with
cyclosporine, prolonged the survival of mice inoculated
with renal cancer cells or T24 human bladder cancer cells
Table 1: Effect of sirolimus in T24 cancer cell line.
Concentration A570 nm A690 nm Mean ± SD
0.525 0.201
0 ng/mL 0.828 0.108 0.557 ± 0.207
0.828 0.201
0.588 0.096
5 ng/mL 0.639 0.078 0.481 ± 0.086
0.72 0.33
0.528 0.054
10 ng/mL 0.468 0.063 0.374 ± 0.117
0.47 0.225
0.516 0.213
40 ng/mL 0.489 0.087 0.310 ± 0.087
0.477 0.25
0.78 0.489
60 ng/mL 0.687 0.354 0.267 ± 0.080
0.339 0.162
0.474 0.288
100 ng/mL 0.573 0.246 0.301 ± 0.104
0.657 0.267
0.501 0.276
150 ng/mL 0.42 0.318 0.22 ± 0.115
0.618 0.285
0.504 0.417
200 ng/mL 0.294 0.255 0.193 ± 0.226
0.576 0.123
0.345 0.264
250 ng/mL 0.3 0.27 0.199 ± 0.249
0.618 0.132Journal of Experimental & Clinical Cancer Research 2009, 28:3 http://www.jeccr.com/content/28/1/3
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[28]. This is an indirect assumption of sirolimus effect
against T24. The present study is the first address this
issue. In the other hand, our team observed similar
results, when we studied the effects of sirolimus in chem-
ical induced urothelial cancers in ICR mice (data submit-
ted). Sirolimus has been shown to inhibit the
proliferation of various tumour cell lines including rhab-
domyosarcoma, neuroblastoma, glioblastoma, small cell
lung cancer, osteosarcoma, pancreatic cancer, breast can-
cer, prostate cancer, murine melanoma, leukaemia, and B-
cell lymphoma [29-33].
Sirolimus enhances the anti-tumour effect of gemcitabine
[34]. Now we intend to verify the efficacy of sirolimous
mTOR inhibition, in other bladder cancer cell lines (5637,
HT1376 and MC). Clinical results show that mTOR inhib-
itors are well tolerated and may induce prolonged stable
disease and tumour regression in cancer patients [24].
Urgent research is needed to evaluate the real place of
sirolimus or similar drugs in urothelial bladder cancer
therapeutic.
Conclusion
Sirolimus inhibits T24 bladder cancer cell proliferation
and decrease cell viability including in clinical dose, there-
fore should be considered to be a promising agents
against bladder cancer. However, more positive data will
be necessary.
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